Alveron Pharma
Nijmegen
About Alveron Pharma
Alveron Pharma develops treatment for hemorrhagic stroke, a severe unmet medical need. Alveron’s drug OKL-1111 strongly reduces hematoma expansion in a mouse model of intracranial hemorrhage. As an injection solution that is ready to use, OKL-1111 is being developed to do away with a laborious pre-treatment process.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $17.1M
- Funding stage: Seed
- Last round: Seed (Dec 2024)
- Website: alveron.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Emergency Medicine, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/alveron-pharma-66875 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.